Hi, I monitor news about antibodies specifically in the biotech industry. These are the news that I have seen that are of interest from April 2026.
🤝 Gilead to acquire Tubulis, adding TUB-040, a NaPi2b targeting ADC for ovarian cancer and a next generation platform to further strengthen oncology pipeline, in up to $5B deal. https://www.gilead.com/news/news-details/2026/gilead-to-acquire-tubulis-adding-potentially-best-in-class-antibody-drug-conjugate-and-next-generation-platform-to-further-strengthen-oncology-pipeline
🤝 CrossBridge Bio to be acquired by Eli Lilly to advance next-generation dual-payload antibody-drug conjugates in $300M deal. https://www.businesswire.com/news/home/20260414133394/en/CrossBridge-Bio-Enters-an-Agreement-to-be-Acquired-by-Eli-Lilly-to-Advance-Next-Generation-Dual-Payload-Antibody-Drug-Conjugates
🥷 Stipple Bio emerges from stealth with $100M Series A financing to advance STP-100, a novel ADC, and cancer pipeline that leverages its pointillist platform. https://stipple.bio/stipple-bio-emerges-from-stealth-with-oversubscribed-100-million-series-a-financing-to-advance-stp-100-into-early-clinical-studies-and-advance-a-precision-oncology-pipeline-that-leverages-its-pointil/
💸 Sidewinder Therapeutics announces $137M Series B financing for bispecific ADCs that target receptor co-complexes that are highly expressed on certain solid tumors. https://sidewinderbio.com/news/sidewinder-therapeutics-announces-137-million-series-b-financing-to-advance-precision-bispecific-adcs-into-clinical-development-for-cancer/
🤝 Korsana Biosciences secures $380M private investment in support of merger agreement with Cyclerion Therapeutics. Korsana to advance shuttled mAb for Alzheimer’s. https://korsana.com/news/cyclerion-therapeutics-and-korsana-biosciences-announce-merger-agreement/
🤝 C4 Therapeutics and Roche to collaborate on degrader-antibody conjugates (DACs) in potential $1B deal. https://ir.c4therapeutics.com/news-releases/news-release-details/c4-therapeutics-expands-long-term-partnership-roche-through-new
🤝 Telix and Regeneron to collaborate on radiopharmaceutical antibody therapies with solid tumor targets in potential $2.1B deal. https://telixpharma.com/news-views/telix-and-regeneron-announce-strategic-radiopharma-collaboration/
💸 Adcendo completes $75M Series C financing to continue advancing first- and best-in-class clinical ADC pipeline for cancers with high unmet medical need. https://adcendo.com/adcendo-aps-completes-75-million-series-c-financing-to-continue-advancing-first-and-best-in-class-clinical-adc-pipeline/
💸 First Tracks Biotherapeutics launches with $180M, advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases. Lead program ANB033 is a CD122 antagonist. https://ir.firsttracksbio.com/news-releases/news-release-details/first-tracks-biotherapeutics-debuts-nasdaq-advance-therapies
💸 Alloy Therapeutics announces $40M Series E to scale from antibody discovery company to tech-enabled biotech infrastructure company. https://www.businesswire.com/news/home/20260415032940/en/Alloy-Therapeutics-Announces-%2440M-Series-E-to-Scale-Tech-Enabled-Biotech-Infrastructure
🔬 Boehringer Ingelheim and Zai Lab to collaborate on DLL3‑targeting T‑cell engager and ADC combination in small cell lung cancer and other neuroendocrine carcinomas. https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/boehringer-ingelheim-and-zai-lab-announce-collaboration-dll3-targeting-t-cell-engager-and-adc
💸 Tacalyx gets €11M to advance lead TACA-targeting ADC program toward the clinic. TCX-201 is aimed at treating gastrointestinal malignancies and other solid tumors. https://www.tacalyx.com/news
🤝 Huahui Health and BeOne Medicines agrees on a $2B deal for HH160, a novel trispecific antibody. https://www.prnewswire.com/news-releases/huahui-health-and-beone-medicines-enter-into-a-global-exclusive-option-license-and-collaboration-agreement-for-innovative-oncology-drug-hh160-302758566.html
🤝 Cue Biopharma gets license from Ascendant Health Sciences Ltd. for dual-mechanism anti-IgE antibody for treatment of allergic diseases in up to $691M deal. https://cuebiopharma.gcs-web.com/news-releases/news-release-details/cue-biopharma-expands-pipeline-exclusive-license-ascendant